Serum CEACAM1 Correlates with Disease Progression and Survival in Malignant Melanoma Patients
Figure 4
Monitoring of sCEACAM1 further stratifies DTH-negative patients into two prognostically distinct groups. The analysis described in Figure 3 was performed exclusively for (a) DTH-negative patients () and (b) DTH-positive patients (). Subgroups sizes were (DTH-) or (DTH+) for decreased sCEACAM1 and (DTH−) or (DTH+) for increased sCEACAM1.
